219 related articles for article (PubMed ID: 26448449)
1. Mass Spectrometric N-Glycan Analysis of Haptoglobin from Patient Serum Samples Using a 96-Well Plate Format.
Zhu J; Wu J; Yin H; Marrero J; Lubman DM
J Proteome Res; 2015 Nov; 14(11):4932-9. PubMed ID: 26448449
[TBL] [Abstract][Full Text] [Related]
2. Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies.
Zhu J; Lin Z; Wu J; Yin H; Dai J; Feng Z; Marrero J; Lubman DM
J Proteome Res; 2014 Jun; 13(6):2986-97. PubMed ID: 24807840
[TBL] [Abstract][Full Text] [Related]
3. Mass-Selected Site-Specific Core-Fucosylation of Serum Proteins in Hepatocellular Carcinoma.
Yin H; Tan Z; Wu J; Zhu J; Shedden KA; Marrero J; Lubman DM
J Proteome Res; 2015 Nov; 14(11):4876-84. PubMed ID: 26403951
[TBL] [Abstract][Full Text] [Related]
4. ESI-LC-MS Method for Haptoglobin Fucosylation Analysis in Hepatocellular Carcinoma and Liver Cirrhosis.
Zhang Y; Zhu J; Yin H; Marrero J; Zhang XX; Lubman DM
J Proteome Res; 2015 Dec; 14(12):5388-95. PubMed ID: 26503433
[TBL] [Abstract][Full Text] [Related]
5. N-linked glycan changes of serum haptoglobin β chain in liver disease patients.
Zhang S; Shu H; Luo K; Kang X; Zhang Y; Lu H; Liu Y
Mol Biosyst; 2011 May; 7(5):1621-8. PubMed ID: 21380457
[TBL] [Abstract][Full Text] [Related]
6. Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.
Peta V; Zhu J; Lubman DM; Huguet S; Imbert-Bismutd F; Bolbach G; Clodic G; Matheron L; Ngo Y; Raluca P; Housset C; Rezai K; Poynard T;
Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):681-691. PubMed ID: 31964615
[TBL] [Abstract][Full Text] [Related]
7. Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma.
Yin H; Lin Z; Nie S; Wu J; Tan Z; Zhu J; Dai J; Feng Z; Marrero J; Lubman DM
J Proteome Res; 2014 Jun; 13(6):2887-96. PubMed ID: 24799124
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of site-specific N-glycans on sera haptoglobin β chain in liver diseases.
Zhang S; Jiang K; Sun C; Lu H; Liu Y
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):1021-9. PubMed ID: 24103369
[TBL] [Abstract][Full Text] [Related]
9. Quantitative liquid chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-specific glycoforms of haptoglobin in liver disease.
Sanda M; Pompach P; Brnakova Z; Wu J; Makambi K; Goldman R
Mol Cell Proteomics; 2013 May; 12(5):1294-305. PubMed ID: 23389048
[TBL] [Abstract][Full Text] [Related]
10. Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma.
Pompach P; Brnakova Z; Sanda M; Wu J; Edwards N; Goldman R
Mol Cell Proteomics; 2013 May; 12(5):1281-93. PubMed ID: 23389049
[TBL] [Abstract][Full Text] [Related]
11. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
12. Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer.
Lin Z; Simeone DM; Anderson MA; Brand RE; Xie X; Shedden KA; Ruffin MT; Lubman DM
J Proteome Res; 2011 May; 10(5):2602-11. PubMed ID: 21417406
[TBL] [Abstract][Full Text] [Related]
13. Protein expression and fucosylated glycans of the serum haptoglobin-{beta} subunit in hepatitis B virus-based liver diseases.
Shu H; Zhang S; Kang X; Li S; Qin X; Sun C; Lu H; Liu Y
Acta Biochim Biophys Sin (Shanghai); 2011 Jul; 43(7):528-34. PubMed ID: 21606158
[TBL] [Abstract][Full Text] [Related]
14. LC-MS/MS isomeric profiling of permethylated N-glycans derived from serum haptoglobin of hepatocellular carcinoma (HCC) and cirrhotic patients.
Huang Y; Zhou S; Zhu J; Lubman DM; Mechref Y
Electrophoresis; 2017 Sep; 38(17):2160-2167. PubMed ID: 28543513
[TBL] [Abstract][Full Text] [Related]
15. Multifucosylated Alpha-1-acid Glycoprotein as a Novel Marker for Hepatocellular Carcinoma.
Tanabe K; Kitagawa K; Kojima N; Iijima S
J Proteome Res; 2016 Sep; 15(9):2935-44. PubMed ID: 27354006
[TBL] [Abstract][Full Text] [Related]
16. Serum profiling based on fucosylated glycoproteins for differentiating between chronic hepatitis B and hepatocellular carcinoma.
Liao J; Zhang R; Qian H; Cao L; Zhang Y; Xu W; Li J; Wu M; Yin Z
Biochem Biophys Res Commun; 2012 Apr; 420(2):308-14. PubMed ID: 22425980
[TBL] [Abstract][Full Text] [Related]
17. Analysis of serum Haptoglobin using glycoproteomics and lectin immunoassay in liver diseases in Hepatitis B virus infection.
Dalal K; Dalal B; Bhatia S; Shukla A; Shankarkumar A
Clin Chim Acta; 2019 Aug; 495():309-317. PubMed ID: 31014754
[TBL] [Abstract][Full Text] [Related]
18. Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches.
Zhu J; Warner E; Parikh ND; Lubman DM
Mass Spectrom Rev; 2019 May; 38(3):265-290. PubMed ID: 30472795
[TBL] [Abstract][Full Text] [Related]
19. Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients.
Mondal G; Saroha A; Bose PP; Chatterjee BP
Glycoconj J; 2016 Apr; 33(2):209-18. PubMed ID: 27034286
[TBL] [Abstract][Full Text] [Related]
20. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus.
Liu XE; Desmyter L; Gao CF; Laroy W; Dewaele S; Vanhooren V; Wang L; Zhuang H; Callewaert N; Libert C; Contreras R; Chen C
Hepatology; 2007 Nov; 46(5):1426-35. PubMed ID: 17683101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
